Insilico Medicine

When Ann Beliën watched her father struggle with age-related diseases that didn’t respond to conventional treatments, she faced a choice that would define her career. She could accept the pharmaceutic

“This is the time to stand up together and say “no” to what the [US] Administration is doing,” said a pharmaceutical industry executive during a January 2025 conference call. Since then, President Tru

Artificial intelligence (AI)-driven drug discovery company Insilico Medicine is fast-tracking its first-in-class small molecule targeting Traf2- and Nck-interacting kinase (TNIK) into a Phase III stud

The number of venture capital mega-rounds of $100m or more plummeted from 11 in January to just three in February, but appear to be on the rise again with five as of mid-March. Flagship Pioneering’s l